Fiche centre
Dent Neurologic Institute
Amherst — United States
Essais liés12clinical trials
VilleAmherstlocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT06159673
Essais cliniques associés
12| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Low Dose Benfotiamine | Alzheimer | Phase 2 | NCT06223360 | A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam) | ACTIVE_NOT_RECRUITING |
| ACP-204 | Alzheimer | Phase 2/3 | NCT06159673 | ACP-204 in Adults With Alzheimer's Disease Psychosis | RECRUITING |
| Donanemab | Alzheimer | Phase 3 | NCT04437511 | A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) | ACTIVE_NOT_RECRUITING |
| Atogepant | Migraine | Phase 3 | NCT03777059 | 12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine | COMPLETED |
| Galcanezumab | Migraine | Phase 3 | NCT04616326 | REBUILD-2 — A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine | ACTIVE_NOT_RECRUITING |
| Neurostimulator | Migraine | Non applicable | NCT06167655 | A PIVOTAL STUDY EVALUATING SAFETY AND EFFICACY OF THE SHIRATRONICS MIGRAINE THERAPY SYSTEM | ACTIVE_NOT_RECRUITING |
| Galcanezumab | Migraine | Phase 3 | NCT03432286 | REBUILD-1 — A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine | ACTIVE_NOT_RECRUITING |
| H.P. Acthar Gel | Migraine | Phase 2 | NCT01813591 | A Two-Arm Study Evaluation H.P. Acthar Injection Gel in Treatment of Chronic Migraines | COMPLETED |
| MT-1186 | Sclérose latérale amyotrophique | Phase 3 | NCT04569084 | Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS | TERMINATED |
| Descartes-08 | Myasthénie | Phase 2 | NCT04146051 | Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG) | ACTIVE_NOT_RECRUITING |
| Zilucoplan | Sclérose latérale amyotrophique | Phase 2/3 | NCT04297683 | HEALEY ALS Platform Trial - Master Protocol | ACTIVE_NOT_RECRUITING |
| PIPE-307 Dose A | SEP | Phase 2 | NCT06083753 | VISTA — Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis | COMPLETED |